News | April 06, 2022
GE Healthcare and Elekta sign global collaboration agreement
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
